Clinical trial
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium…
NCT00191971 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191971 |
|---|---|
| Title | 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen |
| Official title | A Phase II Study of Gemcitabine in Transitional Cell Carcinoma of the Urothelium |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Urologic Neoplasms, Carcinoma, Transitional Cell |
| Intervention type | Drug |
| Interventions | Gemcitabine |
| Enrollment | 40 |
| Start date | Jan 1, 2004 |
| Completion | Sep 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 6, 2007 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: